What should I avoid while taking Chlorpromazine 100mg tablets?

Avoid alcohol. Take with food. Food reduces irritation. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Chlorpromazine 100mg tablets?

Chlorpromazine 100mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Chlorpromazine 100mg tablets?

Chlorpromazine 100mg tablets is the generic name. It is available under brand names including: Chlorpromazine 100mg tablets, Chlorpromazine 100mg tablets, Chlorpromazine 100mg tablets, Chlorpromazine 100mg tablets, Chlorpromazine 100mg tablets and 18 more. (Source: NHS dm+d — Actual Medicinal Products)

Chlorpromazine 100mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

100mg

Oral

Antipsychotic

The prototypical phenothiazine antipsychotic drug.

Active ingredients:

Chlorpromazine

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.02.01

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N05AA01

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Primary care groupBrowse groups

NHS medication clusters used to compare prescribing patterns across GP practices

Antipsychotic

Check interactions for Chlorpromazine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Chlorpromazine

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Chlorpromazine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Chlorpromazine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

23 branded products available

23 productsShow details

23 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Chlorpromazine on the MHRA register

Chlorpromazine 100mg tablets

A A H Pharmaceuticals Ltd

Chlorpromazine 100mg tablets

Teva UK Ltd

Chlorpromazine 100mg tablets

Alliance Healthcare (Distribution) Ltd

Chlorpromazine 100mg tablets

Dr Reddy's Laboratories (UK) Ltd

Chlorpromazine 100mg tablets

Almus Pharmaceuticals Ltd

Chlorpromazine 100mg tablets

Phoenix Healthcare Distribution Ltd

Chlorpromazine 100mg tablets

Sigma Pharmaceuticals Plc

Chlorpromazine 100mg tablets

Genesis Pharmaceuticals Ltd

Chlorpromazine 100mg tablets

Medihealth (Northern) Ltd

Chlorpromazine 100mg tablets

AAH Hillcross

Chlorpromazine 100mg tablets

Northumbria Pharma Ltd

Chlorpromazine 100mg tablets

Accord-UK Ltd

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Price & daily doseShow details

£30.63indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

300 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Levomepromazine 6.25mg tablets

Tablet

6.25mg

Same therapeutic group

Levomepromazine hydrochloride 25mg/5ml oral solution sugar free

Oral solution

25mg/5ml

Same therapeutic group

Levomepromazine 3mg tablets

Tablet

3mg

Same therapeutic group

Levomepromazine 50mg tablets

Tablet

50mg

Same therapeutic group

Levomepromazine 1mg capsules

Capsule

1mg

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Chlorpromazine

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(2)

Psychosis and schizophrenia in adults: prevention and management (CG178)

CG178

Clinical guideline

Updated Mar 2014

Psychosis and schizophrenia in children and young people: recognition and management (CG155)

CG155

Clinical guideline

Updated Oct 2016

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Chlorpromazine

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42268811000001102

dm+d ID

42268811000001102

VTM (Virtual Therapeutic Moiety)

775216005

VMP (Virtual Medicinal Product)

42268811000001102

BNF code

04020100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N05AA01

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

38 found

Half-life

30 hours

Mechanism

Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic…

Food interactions

2 warnings

Human targets

24 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Readily absorbed from the GI tract. Bioavailability varies due to first-pass metabolism by the liver.

Half-life

30 hours

~ 30 hours

Protein binding

90%

> 90% to plasma proteins, primarily albumin

Volume of distribution

20 L/kg

* 20 L/kg

Metabolism

20%

Extensively metabolized in the liver and kidneys. It is extensively metabolized by cytochrome P450 isozymes CYP2D6 (major pathway), CYP1A2 and CYP3A4.…

Elimination

37%

Kidneys, ~ 37% excreted in urine

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Vet approved

Small molecule

About this compound

The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.

Properties:

liquid

Avg. mass: 318.86 Da

DrugBank indication

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Also known as(194)

3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine

3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine

Chlorpromazine

Chlorpromazinum

Clorpromazina

CPZ

N-(3-dimethylaminopropyl)-3-chlorophenothiazine

Dopamine D2 receptor

Dosage forms(79)

Tablet (Oral) — 111.4 mg

Tablet (Oral) — 27.9 mg

Tablet (Oral) — 55.7 mg

Tablet (Oral) — 111.6 mg / tab

Tablet (Oral) — 27.9 mg / tab

Tablet (Oral) — 55.8 mg / tab

Solution / drops (Oral) — 22.2 mg / mL

Syrup (Oral) — 44.5 mg / mL

Molecular properties(18)

Drug interactions(2535)

Known interactions with other medications. Always consult a healthcare professional.

Ivabradine

Moderate

DB09083

Ivabradine may increase the QTc-prolonging activities of Chlorpromazine.

Check this interaction

Desmopressin

Unknown severity

DB00035

The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desmopressin.

Check this interaction

Duloxetine

Major

DB00476

The risk or severity of orthostatic hypotension and syncope can be increased when Chlorpromazine is combined with Duloxetine.

Check this interaction

Levodopa

Major

DB01235

The risk or severity of hypotension and orthostatic hypotension can be increased when Chlorpromazine is combined with Levodopa.

Check this interaction

Risperidone

Moderate

DB00734

Chlorpromazine may increase the hypotensive activities of Risperidone.

Check this interaction

Atropine

Moderate

DB00572

Chlorpromazine may decrease the excretion rate of Atropine which could result in a higher serum level.

Check this interaction

Glycochenodeoxycholic Acid

Moderate

DB02123

Chlorpromazine may decrease the excretion rate of Glycochenodeoxycholic Acid which could result in a higher serum level.

Check this interaction

Pravastatin

Moderate

DB00175

Chlorpromazine may decrease the excretion rate of Pravastatin which could result in a higher serum level.

Check this interaction

Diethylstilbestrol

Moderate

DB00255

Chlorpromazine may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.

Check this interaction

Isradipine

Moderate

DB00270

Chlorpromazine may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Flucloxacillin

Moderate

DB00301

Chlorpromazine may decrease the excretion rate of Flucloxacillin which could result in a higher serum level.

Check this interaction

Indomethacin

Moderate

DB00328

Chlorpromazine may decrease the excretion rate of Indomethacin which could result in a higher serum level.

Check this interaction

Rosiglitazone

Moderate

DB00412

Chlorpromazine may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.

Check this interaction

Spironolactone

Moderate

DB00421

Chlorpromazine may decrease the antihypertensive activities of Spironolactone.

Check this interaction

Cerivastatin

Moderate

DB00439

Chlorpromazine may decrease the excretion rate of Cerivastatin which could result in a higher serum level.

Check this interaction

Diclofenac

Moderate

DB00586

Chlorpromazine may decrease the excretion rate of Diclofenac which could result in a higher serum level.

Check this interaction

Losartan

Moderate

DB00678

Chlorpromazine may decrease the antihypertensive activities of Losartan.

Check this interaction

Fluorescein

Moderate

DB00693

Chlorpromazine may decrease the excretion rate of Fluorescein which could result in a higher serum level.

Check this interaction

Nitrofurantoin

Moderate

DB00698

Chlorpromazine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.

Check this interaction

Naproxen

Moderate

DB00788

Chlorpromazine may decrease the excretion rate of Naproxen which could result in a higher serum level.

Check this interaction

Disulfiram

Moderate

DB00822

Chlorpromazine may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Cefaclor

Moderate

DB00833

Chlorpromazine may decrease the excretion rate of Cefaclor which could result in a higher serum level.

Check this interaction

Tinidazole

Moderate

DB00911

Chlorpromazine may decrease the excretion rate of Tinidazole which could result in a higher serum level.

Check this interaction

Repaglinide

Moderate

DB00912

Chlorpromazine may decrease the excretion rate of Repaglinide which could result in a higher serum level.

Check this interaction

Telmisartan

Moderate

DB00966

Chlorpromazine may decrease the excretion rate of Telmisartan which could result in a higher serum level.

Check this interaction

Ezetimibe

Moderate

DB00973

Chlorpromazine may decrease the excretion rate of Ezetimibe which could result in a higher serum level.

Check this interaction

Sulfamethoxazole

Moderate

DB01015

Chlorpromazine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.

Check this interaction

Fenofibrate

Moderate

DB01039

Chlorpromazine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.

Check this interaction

Nitrendipine

Moderate

DB01054

Chlorpromazine may decrease the excretion rate of Nitrendipine which could result in a higher serum level.

Check this interaction

Rosuvastatin

Moderate

DB01098

Chlorpromazine may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.

Check this interaction

Sulfinpyrazone

Moderate

DB01138

Chlorpromazine may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.

Check this interaction

Ofloxacin

Moderate

DB01165

Chlorpromazine may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Check this interaction

Taurocholic acid

Moderate

DB04348

Chlorpromazine may decrease the excretion rate of Taurocholic acid which could result in a higher serum level.

Check this interaction

Prasterone sulfate

Moderate

DB05804

Chlorpromazine may decrease the excretion rate of Prasterone sulfate which could result in a higher serum level.

Check this interaction

Indocyanine green acid form

Moderate

DB09374

Chlorpromazine may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level.

Check this interaction

Benzbromarone

Moderate

DB12319

Chlorpromazine may decrease the excretion rate of Benzbromarone which could result in a higher serum level.

Check this interaction

Pilsicainide

Moderate

DB12712

Chlorpromazine may decrease the excretion rate of Pilsicainide which could result in a higher serum level.

Check this interaction

Dihydroergocristine

Moderate

DB13345

Chlorpromazine may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.

Check this interaction

Glycyrrhizic acid

Moderate

DB13751

Chlorpromazine may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.

Check this interaction

Loratadine

Moderate

DB00455

Chlorpromazine may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Atorvastatin

Moderate

DB01076

Chlorpromazine may decrease the excretion rate of Atorvastatin which could result in a higher serum level.

Check this interaction

Belantamab mafodotin

Moderate

DB15719

Chlorpromazine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.

Check this interaction

Phenytoin

Moderate

DB00252

The metabolism of Chlorpromazine can be increased when combined with Phenytoin.

Check this interaction

Fosphenytoin

Moderate

DB01320

The metabolism of Chlorpromazine can be increased when combined with Fosphenytoin.

Check this interaction

Deferasirox

Unknown severity

DB01609

The serum concentration of Chlorpromazine can be increased when it is combined with Deferasirox.

Check this interaction

Peginterferon alfa-2b

Unknown severity

DB00022

The serum concentration of Chlorpromazine can be increased when it is combined with Peginterferon alfa-2b.

Check this interaction

Leflunomide

Unknown severity

DB01097

The serum concentration of Chlorpromazine can be decreased when it is combined with Leflunomide.

Check this interaction

Teriflunomide

Unknown severity

DB08880

The serum concentration of Chlorpromazine can be decreased when it is combined with Teriflunomide.

Check this interaction

Valsartan

Moderate

DB00177

Chlorpromazine may decrease the antihypertensive activities of Valsartan.

Check this interaction

Remikiren

Moderate

DB00212

Chlorpromazine may decrease the antihypertensive activities of Remikiren.

Check this interaction

Showing 50 of 2535 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol.

Take With Food

Take with food. Food reduces irritation.

Toxicity & overdose

Agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, restlessness

How it works

Mechanism of action

Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).
Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. This action could also account for psychomotor agitation and amplification of psychosis (very rarely noted in clinical use).

Pharmacodynamics

Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Readily absorbed from the GI tract. Bioavailability varies due to first-pass metabolism by the liver.

Half-life

~ 30 hours

Protein binding

> 90% to plasma proteins, primarily albumin

Volume of distribution

* 20 L/kg

Metabolism

Extensively metabolized in the liver and kidneys. It is extensively metabolized by cytochrome P450 isozymes CYP2D6 (major pathway), CYP1A2 and CYP3A4. Approximately 10 to 12 major metabolite have been identified.

Hydroxylation at positions 3 and 7 of the phenothiazine nucleus and the N-dimethylaminopropyl side chain undergoes demethylation and is also metabolized to an N-oxide. In urine, 20% of chlopromazine and its metabolites are excreted unconjugated in the urine as unchanged drug, demonomethylchlorpromazine, dedimethylchlorpromazine, their sulfoxide metabolites, and chlorpromazine-N-oxide. The remaining 80% consists of conjugated metabolites, principally O-glucuronides and small amounts of ethereal sulfates of the mono- and dihydroxy-derivatives of chlorpromazine and their sulfoxide metabolites.

The major metabolites are the monoglucuronide of N-dedimethylchlorpromazine and 7-hydroxychlorpromazine. Approximately 37% of the administered dose of chlorpromazine is excreted in urine.

Route of elimination

Kidneys, ~ 37% excreted in urine

Drug targets(24)

Proteins and enzymes this drug interacts with in the body

D(2) dopamine receptor

BE0000756

DRD2

antagonist

Specific functiondopamine binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase .
PMID:21645528
Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity)

D(1A) dopamine receptor

BE0000020

DRD1

antagonist

Specific functionarrestin family protein binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase

5-hydroxytryptamine receptor 1A

BE0000291

HTR1A

antagonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:37935376 PMID:37935377 PMID:8138923 PMID:8393041

Also functions as a receptor for various drugs and psychoactive substances .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:38552625 PMID:8138923 PMID:8393041

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:8138923 PMID:8393041

HTR1A is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission: signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores .
PMID:33762731 PMID:35610220
Beta-arrestin family members regulate signaling by mediating both receptor desensitization and resensitization processes .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the response to anxiogenic stimuli PMID:18476671 PMID:20363322 PMID:20945968

5-hydroxytryptamine receptor 2A

BE0000451

HTR2A

antagonist

Specific function1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:1330647 PMID:18703043 PMID:19057895 PMID:21645528 PMID:22300836 PMID:35084960 PMID:38552625

Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD) .
PMID:28129538 PMID:35084960
Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors .
PMID:28129538 PMID:35084960
HTR2A is coupled to G(q)/G(11) G alpha proteins and activates phospholipase C-beta, releasing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers that modulate the activity of phosphatidylinositol 3-kinase and promote the release of Ca(2+) ions from intracellular stores, respectively .
PMID:18703043 PMID:28129538 PMID:35084960

Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways .
PMID:28129538 PMID:35084960
Affects neural activity, perception, cognition and mood .
PMID:18297054
Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction (By similarity)

Alpha-1A adrenergic receptor

BE0000501

ADRA1A

antagonist

Specific functionalpha1-adrenergic receptor activity

Cellular location

Nucleus membrane

General function & pharmacology

This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes

Metabolizing enzymes(5)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP2D6Cytochrome P450 2D6

substrate

inhibitor

CYP1A2Cytochrome P450 1A2

substrate

CYP2E1Cytochrome P450 2E1

inhibitor

CYP3A4Cytochrome P450 3A4

inducer

BCHECholinesterase

inhibitor

Transporters(2)

Proteins that transport this drug across cell membranes

ATP-dependent translocase ABCB1

BE0001032

ABCB1

substrate

inhibitor

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548

Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218

Bile salt export pump

BE0000703

ABCB11

inhibitor

Specific functionABC-type bile acid transporter activity

Cellular location

Apical cell membrane

General function & pharmacology

Catalyzes the transport of the major hydrophobic bile salts, such as taurine and glycine-conjugated cholic acid across the canalicular membrane of hepatocytes in an ATP-dependent manner, therefore participates in hepatic bile acid homeostasis and consequently to lipid homeostasis through regulation of biliary lipid secretion in a bile salts dependent manner .
PMID:15791618 PMID:16332456 PMID:18985798 PMID:19228692 PMID:20010382 PMID:20398791 PMID:22262466 PMID:24711118 PMID:29507376 PMID:32203132

Transports taurine-conjugated bile salts more rapidly than glycine-conjugated bile salts .
PMID:16332456
Also transports non-bile acid compounds, such as pravastatin and fexofenadine in an ATP-dependent manner and may be involved in their biliary excretion PMID:15901796 PMID:18245269

Carriers(1)

Proteins that carry this drug through the body

Albumin

BE0000530

ALB

Specific functionantioxidant activity

Cellular location

Secreted

General function & pharmacology

Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). Major zinc transporter in plasma, typically binds about 80% of all plasma zinc .
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).

Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).

Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017

Scientific references(1)

Leucht S., Wahlbeck K., Hamann J., Kissling W.

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.

The Lancet

2003361(9369):1581-1589. doi: 10.1016/s0140-6736(03)13306-5

PMID: 12747876 DOI: 10.1016/s0140-6736(03)13306-5

ATC classification(1 code)

ATC N05AA01

Affected organisms(1)

Humans and other mammals

International brands(7)

Salt forms(1)

Chlorpromazine hydrochloride(DBSALT000026)

Experimental properties(7)

External resources(3)

RxList PDRhealth Drugs.com

Protein Data Bank entries(10)

Commercial products(275)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Chlorpromazine

DB00477

CAS number

50-53-3

UNII (FDA)

U42B7VYA4P

InChI Key (molecular fingerprint)

ZPEIMTDSQAKGNT-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

8017

Drugs Product Database (DPD)

20237

ChEBI

3647

PubChem Compound

2726

PubChem Substance

46508395

KEGG Compound

C06906

KEGG Drug

D00270

ChemSpider

2625

BindingDB

50001888

PharmGKB

PA448964

PDB

Z80

Therapeutic Targets Database

DAP000374

IUPHAR

Guide to Pharmacology

Wikipedia

Chlorpromazine

ChEMBL

CHEMBL71

ZINC

ZINC000000044027

RxCUI

2403

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3023

GenAtlas

DRD2

GeneCards

DRD2

GenBank Gene Database

M30625

GenBank Protein Database

181432

IUPHAR

215

Guide to Pharmacology

215

UniProtKB

P14416

UniProt Accession

DRD2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3020

GenAtlas

DRD1

GeneCards

DRD1

GenBank Gene Database

X55760

GenBank Protein Database

30397

IUPHAR

214

Guide to Pharmacology

214

UniProtKB

P21728

UniProt Accession

DRD1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5286

GenAtlas

HTR1A

GeneCards

HTR1A

GenBank Gene Database

M28269

GenBank Protein Database

189928

IUPHAR

Guide to Pharmacology

UniProtKB

P08908

UniProt Accession

5HT1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5293

GenAtlas

HTR2A

GeneCards

HTR2A

GenBank Gene Database

S42168

GenBank Protein Database

36431

IUPHAR

Guide to Pharmacology

UniProtKB

P28223

UniProt Accession

5HT2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:277

GenAtlas

ADRA1A

GeneCards

ADRA1A

GenBank Gene Database

D25235

GenBank Protein Database

433201

IUPHAR

Guide to Pharmacology

UniProtKB

P35348

UniProt Accession

ADA1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:278

GenAtlas

ADRA1B

GeneCards

ADRA1B

GenBank Gene Database

M99589

IUPHAR

Guide to Pharmacology

UniProtKB

P35368

UniProt Accession

ADA1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5182

GenAtlas

HRH1

GeneCards

HRH1

GenBank Gene Database

Z34897

GenBank Protein Database

510296

IUPHAR

262

Guide to Pharmacology

262

UniProtKB

P35367

UniProt Accession

HRH1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6251

GenAtlas

KCNH2

GeneCards

KCNH2

GenBank Gene Database

U04270

GenBank Protein Database

487738

IUPHAR

572

Guide to Pharmacology

572

UniProtKB

Q12809

UniProt Accession

KCNH2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3020

GenAtlas

DRD1

GeneCards

DRD1

GenBank Gene Database

X55760

GenBank Protein Database

30397

IUPHAR

214

Guide to Pharmacology

214

UniProtKB

P21728

UniProt Accession

DRD1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3026

GenAtlas

DRD5

GeneCards

DRD5

GenBank Gene Database

X58454

GenBank Protein Database

32049

IUPHAR

218

Guide to Pharmacology

218

UniProtKB

P21918

UniProt Accession

DRD5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3024

GenAtlas

DRD3

GeneCards

DRD3

GenBank Gene Database

U32499

GenBank Protein Database

927342

IUPHAR

216

Guide to Pharmacology

216

UniProtKB

P35462

UniProt Accession

DRD3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5295

GenAtlas

HTR2C

GeneCards

HTR2C

GenBank Gene Database

M81778

GenBank Protein Database

338028

IUPHAR

Guide to Pharmacology

UniProtKB

P28335

UniProt Accession

5HT2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:277

GenAtlas

ADRA1A

GeneCards

ADRA1A

GenBank Gene Database

D25235

GenBank Protein Database

433201

IUPHAR

Guide to Pharmacology

UniProtKB

P35348

UniProt Accession

ADA1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:278

GenAtlas

ADRA1B

GeneCards

ADRA1B

GenBank Gene Database

M99589

IUPHAR

Guide to Pharmacology

UniProtKB

P35368

UniProt Accession

ADA1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:280

GenAtlas

ADRA1D

GeneCards

ADRA1D

GenBank Gene Database

M76446

GenBank Protein Database

177807

IUPHAR

Guide to Pharmacology

UniProtKB

P25100

UniProt Accession

ADA1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:281

GenAtlas

ADRA2A

GeneCards

ADRA2A

GenBank Gene Database

M23533

GenBank Protein Database

178196

IUPHAR

Guide to Pharmacology

UniProtKB

P08913

UniProt Accession

ADA2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:282

GenAtlas

ADRA2B

GeneCards

ADRA2B

GenBank Gene Database

M34041

GenBank Protein Database

178198

IUPHAR

Guide to Pharmacology

UniProtKB

P18089

UniProt Accession

ADA2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:283

GenAtlas

ADRA2C

GeneCards

ADRA2C

GenBank Gene Database

J03853

GenBank Protein Database

178194

IUPHAR

Guide to Pharmacology

UniProtKB

P18825

UniProt Accession

ADA2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1950

GenAtlas

CHRM1

GeneCards

CHRM1

GenBank Gene Database

X52068

GenBank Protein Database

34451

IUPHAR

Guide to Pharmacology

UniProtKB

P11229

UniProt Accession

ACM1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1952

GenAtlas

CHRM3

GeneCards

CHRM3

GenBank Gene Database

X15266

GenBank Protein Database

32324

IUPHAR

Guide to Pharmacology

UniProtKB

P20309

UniProt Accession

ACM3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5301

GenAtlas

HTR6

GeneCards

HTR6

GenBank Gene Database

L41147

GenBank Protein Database

1162924

IUPHAR

Guide to Pharmacology

UniProtKB

P50406

UniProt Accession

5HT6R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5302

GenAtlas

HTR7

GeneCards

HTR7

GenBank Gene Database

U68487

GenBank Protein Database

1857143

IUPHAR

Guide to Pharmacology

UniProtKB

P34969

UniProt Accession

5HT7R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3025

GenAtlas

DRD4

GeneCards

DRD4

GenBank Gene Database

L12398

GenBank Protein Database

291946

IUPHAR

217

Guide to Pharmacology

217

UniProtKB

P21917

UniProt Accession

DRD4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3026

GenAtlas

DRD5

GeneCards

DRD5

GenBank Gene Database

X58454

GenBank Protein Database

32049

IUPHAR

218

Guide to Pharmacology

218

UniProtKB

P21918

UniProt Accession

DRD5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5293

GenAtlas

HTR2A

GeneCards

HTR2A

GenBank Gene Database

S42168

GenBank Protein Database

36431

IUPHAR

Guide to Pharmacology

UniProtKB

P28223

UniProt Accession

5HT2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5294

GenAtlas

HTR2B

GeneCards

HTR2B

GenBank Gene Database

X77307

GenBank Protein Database

475198

IUPHAR

Guide to Pharmacology

UniProtKB

P41595

UniProt Accession

5HT2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5295

GenAtlas

HTR2C

GeneCards

HTR2C

GenBank Gene Database

M81778

GenBank Protein Database

338028

IUPHAR

Guide to Pharmacology

UniProtKB

P28335

UniProt Accession

5HT2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11120

GenAtlas

SMPD1

GeneCards

SMPD1

GenBank Gene Database

M59916

GenBank Protein Database

179095

Guide to Pharmacology

2514

UniProtKB

P17405

UniProt Accession

ASM_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8498

GenAtlas

ORM1

GeneCards

ORM1

GenBank Gene Database

X02544

GenBank Protein Database

757907

UniProtKB

P02763

UniProt Accession

A1AG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8499

GeneCards

ORM2

GenBank Gene Database

BC015964

GenBank Protein Database

16359000

UniProtKB

P19652

UniProt Accession

A1AG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:17383

GenAtlas

HRH4

GeneCards

HRH4

GenBank Gene Database

AB044934

GenBank Protein Database

10241847

IUPHAR

265

Guide to Pharmacology

265

UniProtKB

Q9H3N8

UniProt Accession

HRH4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1442

GeneCards

CALM1

UniProtKB

P0DP23

UniProt Accession

CALM1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1445

GeneCards

CALM2

UniProtKB

P0DP24

UniProt Accession

CALM2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1449

GeneCards

CALM3

UniProtKB

P0DP25

UniProt Accession

CALM3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2631

GeneCards

CYP2E1

GenBank Gene Database

J02625

GenBank Protein Database

181360

Guide to Pharmacology

1330

UniProtKB

P05181

UniProt Accession

CP2E1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:983

GenAtlas

BCHE

GeneCards

BCHE

GenBank Gene Database

M32391

GenBank Protein Database

1311630

Guide to Pharmacology

2471

UniProtKB

P06276

UniProt Accession

CHLE_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:399

GenAtlas

ALB

GeneCards

ALB

GenBank Gene Database

V00494

GenBank Protein Database

28590

UniProtKB

P02768

UniProt Accession

ALBU_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:40

GenAtlas

ABCB1

GeneCards

ABCB1

GenBank Gene Database

M14758

GenBank Protein Database

307180

Guide to Pharmacology

768

UniProtKB

P08183

UniProt Accession

MDR1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:42

GenAtlas

ABCB11

GeneCards

ABCB11

GenBank Gene Database

AF091582

GenBank Protein Database

3873243

Guide to Pharmacology

778

UniProtKB

O95342

UniProt Accession

ABCBB_HUMAN

International reference pricing

11 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.17/tablet

To $8.04/ml

Chlorpromazine 25 mg tablet

$0.17/tablet

Chlorpromazine 50 mg tablet

$0.30/tablet

Chlorpromazine 10 mg tablet

$0.32/tablet

ChlorproMAZINE HCl 10 mg tablet

$0.37/tablet

Chlorpromazine 100 mg tablet

$0.39/tablet

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Chlorpromazine 100mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(2)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
32

Chemical identifiers

Chlorpromazine

Additional database identifiers

International reference pricing

DrugBank citations

Chlorpromazine 100mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(2)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science32

Chemical identifiers

Chlorpromazine

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
32